Brief: Durect Corporation Announces Phase 3 Registrational Trial Design For Larsucosterol In Alcohol-Associated Hepatitis
25/09/2024 13:07
Sept 25 (Reuters) - DURECT Corp DRRX.O :
* DURECT CORPORATION ANNOUNCES PHASE 3 REGISTRATIONAL TRIAL
DESIGN
FOR LARSUCOSTEROL IN ALCOHOL-ASSOCIATED HEPATITIS
* DURECT CORP - PHASE 3 TRIAL TO ENROLL 200 U.S. PATIENTS
* DURECT CORP - PHASE 3 TRIAL TO MEASURE 90-DAY SURVIVAL
ENDPOINT
Source text for Eikon: ID:nPnb12qx6a
Further company coverage: DRRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DURECT
See all newsBrief: Bausch Health Completes Acquisition Of Durect Corporation, Expanding Late-Stage Liver Disease Portfolio
Durect Corp Reports Results For The Quarter Ended June 30: Earnings Summary
Brief: Durect Bausch Health Extend Tender Offer Date To Aug 12 - SEC Filing
Durect Corp Expected To Post A Loss Of 12 Cents A Share: Earnings Preview
Durect Corp Reports Results For The Quarter Ended March 31: Earnings Summary